Cover Image
Market Research Report

Acute Myeloid Leukemia (AML) - Pipeline Insight, 2020

Published by DelveInsight Business Research LLP Product code 923243
Published Content info
Delivery time: 1-2 business days
Price
Back to Top
Acute Myeloid Leukemia (AML) - Pipeline Insight, 2020
Published: January 1, 2020 Content info:
Description

Acute Myeloid Leukemia (AML) Overview

"Acute Myeloid Leukemia (AML) Pipeline Insight, 2020" Report By DelveInsight Outlays Comprehensive Insights Of Present Clinical Development Scenario And Growth Prospects Across The Acute Myeloid Leukemia (AML) Market. A Detailed Picture Of The Acute Myeloid Leukemia (AML) Pipeline Landscape Is Provided, Which Includes The Disease Overview And Acute Myeloid Leukemia (AML) Treatment Guidelines.

The Assessment Part Of The Report Embraces In-Depth Acute Myeloid Leukemia (AML) Commercial Assessment And Clinical Assessment Of The Acute Myeloid Leukemia (AML) Pipeline Products From The Pre-Clinical Developmental Phase To The Marketed Phase.

In The Report, A Detailed Description Of The Drug Is Proffered Including Mechanism Of Action Of The Drug, Clinical Studies, NDA Approvals (If Any), And Product Development Activities Comprising The Technology, Acute Myeloid Leukemia (AML) Collaborations, Licensing, Mergers And Acquisition, Funding, Designations, And Other Product-Related Details.

Acute Myeloid Leukemia (AML) Of Pipeline Development Activities

The Report Provides Insights Into:

  • All Of The Companies That Are Developing Therapies For The Treatment Of Acute Myeloid Leukemia (AML) With Aggregate Therapies Developed By Each Company For The Same.
  • Different Therapeutic Candidates Segmented Into Early-Stage, Mid-Stage And Late Stage Of Development For The Acute Myeloid Leukemia (AML) Treatment.
  • Acute Myeloid Leukemia (AML) Key Players Involved In Targeted Therapeutics Development With Respective Active And Inactive (Dormant Or Discontinued) Projects.
  • Drugs Under Development Based On The Stage Of Development, Route Of Administration, Target Receptor, Monotherapy Or Combination Therapy, A Different Mechanism Of Action, And Molecular Type.
  • Detailed Analysis Of Collaborations (Company-Company Collaborations And Company-Academia Collaborations), Licensing Agreement And Financing Details For Future Advancement Of Acute Myeloid Leukemia (AML) Market.
  • The Report Is Built Using Data And Information Traced From The Researcher's Proprietary Databases, Company/University Websites, Clinical Trial Registries, Conferences, SEC Filings, Investor Presentations, And Featured Press Releases From Company/University Web Sites And Industry-Specific Third-Party Sources, Etc.

Acute Myeloid Leukemia (AML) Analytical Perspective By DelveInsight

  • In-Depth Acute Myeloid Leukemia (AML) Commercial Assessment Of Products

This Report Provides A Comprehensive Commercial Assessment Of Therapeutic Drugs That Have Been Included, Which Comprises Of Collaborations, Licensing, And Acquisition Deal Value Trends. The Report Also Covers Company-Company Collaborations (Licensing/Partnering), Company-Academia Collaborations, And Acquisition Analysis In Both Graphical And Tabulated Form In A Detailed Manner.

  • Acute Myeloid Leukemia (AML) Clinical Assessment Of Products

The Report Comprises Of Comparative Clinical Assessment Of Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type Across This Indication.

Scope Of The Report

  • The Acute Myeloid Leukemia (AML) Report Provides An Overview Of Therapeutic Pipeline Activity And Therapeutic Assessment Of The Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type For Acute Myeloid Leukemia (AML) Across The Complete Product Development Cycle, Including All Clinical And Nonclinical Stages.
  • It Comprises Of Detailed Profiles Of Acute Myeloid Leukemia (AML) Therapeutic Products With Key Coverage Of Developmental Activities, Including Technology, Collaborations, Licensing, Mergers And Acquisition, Funding, Designations And Other Product-Related Details
  • Detailed Acute Myeloid Leukemia (AML) Research And Development Progress And Trial Details, Results Wherever Available, Are Also Included In The Pipeline Study.
  • Coverage Of Dormant And Discontinued Pipeline Projects Along With The Reasons If Available Across Acute Myeloid Leukemia (AML).

Report Highlights

  • A Better Understanding of Disease Pathogenesis Contributing To The Development Of Novel Therapeutics For Acute Myeloid Leukemia (AML).
  • In The Coming Years, The Acute Myeloid Leukemia (AML) Market Is Set To Change Due To The Rising Awareness Of The Disease, And Incremental Healthcare Spending Across The World; Which Would Expand The Size Of The Market To Enable The Drug Manufacturers To Penetrate More Into The Market.
  • The Companies And Academics That Are Working To Assess Challenges And Seek Opportunities That Could Influence Acute Myeloid Leukemia (AML) R&D. The Therapies Under Development Are Focused On Novel Approaches To Treat/Improve The Disease Condition.
  • A Detailed Portfolio of Major Pharma Players Who Are Involved In Fueling The Acute Myeloid Leukemia (AML) Treatment Market. Several Potential Therapies For Acute Myeloid Leukemia (AML) Are Under Investigation. With The Expected Launch Of These Emerging Therapies, It Is Expected That There Will Be A Significant Impact On The Acute Myeloid Leukemia (AML) Market Size In The Coming Years.
  • Our In-Depth Analysis Of The Pipeline Assets (In Early-Stage, Mid-Stage And Late Stage Of Development For The Treatment Of Acute Myeloid Leukemia (AML) ) Includes Therapeutic Assessment And Comparative Analysis. This Will Support The Clients In The Decision-Making Process Regarding Their Therapeutic Portfolio By Identifying The Overall Scenario Of The Research And Development Activities.

Key Questions

  • What Are The Current Options For Acute Myeloid Leukemia (AML) Treatment?
  • How Many Companies Are Developing Therapies For The Treatment Of Acute Myeloid Leukemia (AML)?
  • What Are The Principal Therapies Developed By These Companies In The Industry?
  • How Many Therapies Are Developed By Each Company For The Treatment Of Acute Myeloid Leukemia (AML)?
  • How Many Acute Myeloid Leukemia (AML) Emerging Therapies Are In Early-Stage, Mid-Stage, And Late Stage Of Development For The Treatment Of Acute Myeloid Leukemia (AML)?
  • Out Of Total Pipeline Products, How Many Therapies Are Given As A Monotherapy And In Combination With Other Therapies?
  • What Are The Key Collaborations (Industry-Industry, Industry-Academia), Mergers And Acquisitions, And Major Licensing Activities That Will Impact Acute Myeloid Leukemia (AML) Market?
  • Which Are The Dormant And Discontinued Products And The Reasons For The Same?
  • What Is The Unmet Need For Current Therapies For The Treatment Of Acute Myeloid Leukemia (AML)?
  • What Are The Recent Novel Therapies, Targets, Mechanisms Of Action And Technologies Developed To Overcome The Limitation Of Existing Acute Myeloid Leukemia (AML) Therapies?
  • What Are The Clinical Studies Going On For Acute Myeloid Leukemia (AML) And Their Status?
  • What Are The Results Of The Clinical Studies And Their Safety And Efficacy?
  • What Are The Key Designations That Have Been Granted For The Emerging Therapies For Acute Myeloid Leukemia (AML)?
  • How Many Patents Are Granted And Pending For The Emerging Therapies For The Treatment Of Acute Myeloid Leukemia (AML)?
Table of Contents
Product Code: DIPI0871

Table of Contents

1. Report Introduction

2. Acute Myeloid Leukemia (AML)

  • 2.1. Overview
  • 2.2. History
  • 2.3. Acute Myeloid Leukemia (AML) Symptoms
  • 2.4. Causes

2.5.Pathophysiology

  • 2.6. Acute Myeloid Leukemia (AML) Diagnosis
    • 2.6.1. Diagnostic Guidelines

3. Acute Myeloid Leukemia (AML) Current Treatment Patterns

  • 3.1. Acute Myeloid Leukemia (AML) Treatment Guidelines

4. Acute Myeloid Leukemia (AML) - DelveInsight's Analytical Perspective

  • 4.1. In-depth Commercial Assessment
    • 4.1.1. Acute Myeloid Leukemia (AML) companies collaborations, Licensing, Acquisition -Deal Value Trends
      • 4.1.1.1. Assessment Summary
    • 4.1.2. Acute Myeloid Leukemia (AML) Collaboration Deals
      • 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
      • 4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
      • 4.1.2.3. Acute Myeloid Leukemia (AML) Acquisition Analysis

5. Therapeutic Assessment

  • 5.1. Clinical Assessment of Pipeline Drugs
    • 5.1.1. Assessment by Phase of Development
    • 5.1.2. Assessment by Product Type (Mono / Combination)
      • 5.1.2.1. Assessment by Stage and Product Type
    • 5.1.3. Assessment by Route of Administration
      • 5.1.3.1. Assessment by Stage and Route of Administration
    • 5.1.4. Assessment by Molecule Type
      • 5.1.4.1. Assessment by Stage and Molecule Type
    • 5.1.5. Assessment by MOA
      • 5.1.5.1. Assessment by Stage and MOA
    • 5.1.6. Assessment by Target
      • 5.1.6.1. Assessment by Stage and Target

6. Acute Myeloid Leukemia (AML) Late Stage Products (Phase-III)

7. Acute Myeloid Leukemia (AML) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Acute Myeloid Leukemia (AML) Discontinued Products

13. Acute Myeloid Leukemia (AML) Product Profiles

  • 13.1. Drug Name: Company
    • 13.1.1. Product Description
      • 13.1.1.1. Product Overview
      • 13.1.1.2. Mechanism of action
    • 13.1.2. Research and Development
      • 13.1.2.1. Clinical Studies
    • 13.1.3. Product Development Activities
      • 13.1.3.1. Collaboration
      • 13.1.3.2. Agreements
      • 13.1.3.3. Acquisition
      • 13.1.3.4. Patent Detail
    • 13.1.4. Tabulated Product Summary
      • 13.1.4.1. General Description Table

Detailed information in the report?

14. Acute Myeloid Leukemia (AML) Key Companies

15. Acute Myeloid Leukemia (AML) Key Products

16. Dormant and Discontinued Products

  • 16.1. Dormant Products
    • 16.1.1. Reasons for being dormant
  • 16.2. Discontinued Products
    • 16.2.1. Reasons for the discontinuation

17. Acute Myeloid Leukemia (AML) Unmet Needs

18. Acute Myeloid Leukemia (AML) Future Perspectives

19. Acute Myeloid Leukemia (AML) Analyst Review

20. Appendix

21. Report Methodology

  • 21.1. Secondary Research
  • 21.2. Expert Panel Validation

List of Tables

  • Table 1: Acute Myeloid Leukemia (AML) Diagnostic Guidelines
  • Table 2: Acute Myeloid Leukemia (AML) Treatment Guidelines
  • Table 3: Assessment Summary
  • Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis
  • Table 5: Acute Myeloid Leukemia (AML) Acquisition Analysis
  • Table 6: Assessment by Phase of Development
  • Table 7: Assessment by Product Type (Mono / Combination)
  • Table 8: Assessment by Stage and Product Type
  • Table 9: Assessment by Route of Administration
  • Table 10: Assessment by Stage and Route of Administration
  • Table 11: Assessment by Molecule Type
  • Table 12: Assessment by Stage and Molecule Type
  • Table 13: Assessment by MOA
  • Table 14: Assessment by Stage and MOA
  • Table 15: Assessment by Target
  • Table 16: Assessment by Stage and Target
  • Table 17: Acute Myeloid Leukemia (AML) Late Stage Products (Phase-III)
  • Table 18: Acute Myeloid Leukemia (AML) Mid Stage Products (Phase-II)
  • Table 19: Acute Myeloid Leukemia (AML) Early Stage Products (Phase-I)
  • Table 20: Pre-clinical and Discovery Stage Products
  • Table 21: Inactive Products
  • Table 22: Dormant Products
  • Table 23: Discontinued Products

List of Figures

  • Figure 1: Disease Overview
  • Figure 2: History
  • Figure 3: Symptoms
  • Figure 4: Causes
  • Figure 5: Pathophysiology
  • Figure 6: Diagnostic Guidelines
  • Figure 7: Treatment Guidelines
  • Figure 8: Acute Myeloid Leukemia (AML) companies collaborations, Licensing, Acquisition -Deal Value Trends
  • Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis
  • Figure 10: Acute Myeloid Leukemia (AML) Acquisition Analysis
  • Figure 11: Assessment by Phase of Development
  • Figure 12: Assessment by Product Type (Mono / Combination)
  • Figure 13: Assessment by Stage and Product Type
  • Figure 14: Assessment by Route of Administration
  • Figure 15: Assessment by Stage and Route of Administration
  • Figure 16: Assessment by Molecule Type
  • Figure 17: Assessment by Stage and Molecule Type
  • Figure 18: Assessment by MOA
  • Figure 19: Assessment by Stage and MOA
  • Figure 20: Late Stage Products (Phase-III)
  • Figure 21: Mid Stage Products (Phase-II)
  • Figure 22: Early Stage Products (Phase-I)
  • Figure 23: Pre-clinical and Discovery Stage Products
  • Figure 24: Inactive Products
  • Figure 25: Dormant Products
  • Figure 26: Discontinued Products
  • Figure 27: Unmet Needs
Back to Top